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We describe the case of a young patient with a history of non-resolving pneumonia. She was diagnosed
with a limited form of Granulomatosis with Polyangiitis (GPA), by percutaneous core needle lung biopsy.
In this report, we discuss the deﬁnition and clinical implications of limited GPA, treatment options, and
highlight the importance of considering vasculitis in the differential diagnosis of non-resolving
pneumonia.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Case presentation
A 48 year-old woman presented to an outpatient clinic with a
two-week history of non-productive cough and general malaise.
She endorsed a unilateral pruritic red palmar rash. She denied
hemoptysis, fever, nasal symptoms, acid reﬂux, arthralgias, or
constitutional symptoms. Past medical history included remote
symptoms of migratory arthralgias (several months prior to her
presentation), and a remote history of transient left optic neuritis.
Social history revealed no tobacco, occupational, or environmental
exposures.
On initial presentation, her vital signs were stable and the
physical examination was unremarkable. Laboratory investigations
showed normal cell counts, hemoglobin, chemistry, creatinine, and
liver function tests. Urinalysis was positive for moderate red blood
cells, however the patient was menstruating at the time. There was
no proteinuria and no casts. Her chest radiograph showed airspace
disease in the right mid lung ﬁeld, and she was diagnosed with a
lobar pneumonia. A ten-day course of moxiﬂoxacin was prescribed
for treatment of pneumonia.
At follow up 10 days later, her cough did not improve. A
computed tomography (CT) scan showed a 6 cm mass-like area of
consolidation with small cavities in the right middle lobe, and well211, General Campus, Ottawa
Ltd. This is an open access article udeﬁned solid nodules in the periphery of the left lower lobe (Fig. 1).
The differential diagnosis for the CT ﬁndings included an atyp-
ical pneumonia, possibly fungal in origin, malignancy, septic
emboli, or vasculitis.
Serologies for Histoplasma capsulatum and Blastomyces derma-
titidiswere negative. Blood cultures grew Propionobacterium acnes
but only in a single culture bottle. Anti-cytoplasmic nuclear anti-
bodies were positive with c-ANCA at a concentration of 8 AI units.
The patient, still clinically stable, was admitted to hospital for
further investigation of suspected ANCA-associated vasculitis.
Erythrocyte sedimentation rate and C-reactive protein were
elevated at 58 mm/hr and 18.3 mg/L, respectively. Anti-nuclear
antibodies and extractable nuclear antigens were negative. Com-
plement assays were normal and anti-PR3 antibodies were high,
measuring 417 chemiluminescent units. Fluoroscopically guided
percutaneous ﬁne and core needle biopsies were obtained from the
right middle lobe mass.
The core needle biopsies showed necrotizing granulomatous
inﬂammation. The granulomas consisted mainly of giant cells and
epithelioid histiocytes surrounding areas of suppurative basophilic
necrosis and embedded in a polymorphous inﬂammatory inﬁltrate.
The elastic stain demonstrated areas of vasculitis with fragmenta-
tion of the elastic layer. The special stains as well as tissue cultures
for fungi and mycobacteria were negative. This constellation of
features was diagnostic of granulomatosis with polyangiitis (GPA)
(Fig. 2).
Following a negative tuberculin skin test and normal hepatitis
serology, she was started on high dose prednisone (1 mg/kg), andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. (A) Chest radiograph (posteroanterior view) reveals right mid lung zone mass (arrow) and multiple pulmonary nodules (arrows) in left lung. (B) Chest computed tomography
in axial plane, in lung window, conﬁrms presence of right middle lobe mass (white arrow), with well deﬁned borders, lobulated outline and cavitation (black arrow).
Fig. 2. The image shows extensive mixed type necrosis with a focal rounded area of suppurative necrosis on the left side (dashed line) (H&E stain, 100). The elastic stain in the
inset highlights, in black, the elastic layer of the blood vessel wall, which is partially destroyed (arrows) by the inﬂammation (Verhoeff stain, 200).
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aise improved. Further investigation with bloodwork, urinalysis,
and nasal examination showed no evidence of multi- organ
involvement. On repeat chest radiograph four weeks after treat-
ment, there was interval improvement in the airspace disease
density (Fig. 3).
2. Discussion
GPA, formerly known as ‘Wegener’s Granulomatosis’, is a sys-
temic necrotizing granulomatous small and medium vessel vascu-
litis commonly affecting the upper and lower respiratory tracts, and
kidneys. Early recognition, diagnosis, and treatment of GPA is
imperative, as the mortality rate is >80% if left untreated [1,2].
Like other vasculitides, the clinical presentation of GPA is
diverse and can involve any organ system. Most commonly, oto-
lanryngeal involvement occurs (76% of cases), and manifests as
bloody nasal discharge, nasal crusting or ulceration, and conductive
hearing loss [1]. Approximately half of patients with GPA also
endorse constitutional symptoms (fever, malaise, anorexia, weight
loss) and renal involvement including hematuria, red blood cellcasts, and renal failure [1]. Pulmonary involvement occurs in 60% of
cases, most commonly presenting as cough, dyspnea, and hemop-
tysis from cavitating nodules, nonspeciﬁc airspace inﬁltrates, and
alveolar hemorrhage [1]. However, isolated pulmonary involve-
ment from GPA is rare [3]. In a study of 77 patients with GPA, iso-
lated pulmonary involvement occurred in only 9% (7/77) [3].
Mucosal, cutaneous, cardiovascular, gastrointestinal, and nervous
system involvement have also been reported, but occur much less
commonly [1].
A high degree of clinical suspicion is imperative in order tomake
an early diagnosis. Although GPA is associated with a constellation
of pathological features, a deﬁnite diagnosis requires demonstra-
tion of necrotizing vasculitis in an affected organ [4]. When there is
lung involvement, the choice of biopsy technique is based on the
balance of the invasiveness of the procedure and the histological
yield of the obtained specimen. Surgical lung biopsy has an
established high diagnostic yield, but has appreciable associated
morbidity, including pain and prolonged recovery times [3,5,6]. The
efﬁcacy of transbronchial biopsy is less; in one series only 12% (2/
17) alveolar, and 33% (7/21) lower respiratory tract biopsies had
sufﬁcient pathologic characteristics which led to a diagnosis [7]. In
Fig. 3. Follow up chest radiograph (posteroanterior view) performed following treat-
ment, demonstrates signiﬁcant decrease in size of largest lesion in mid lung zone
(white arrow).
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raise the possibility of GPA in the appropriate clinical context, but
are usually not helpful in conﬁrming the diagnosis [7]. Core needle
biopsy, such as the one used in our case, has been shown to provide
a deﬁnitive diagnosis in a proportion of cases, but the data
regarding the yield of the procedure is limited and not speciﬁc for
limited pulmonary vasculitis [8]. Overall, core needle biopsies are
superior to ﬁne needle aspiration for non-neoplastic inﬂammatory
lung conditions [9]. Fine-needle aspiration biopsies are helpful in
ruling out malignancy and obtaining tissue for culture, but cannot
conﬁrm the diagnosis of GPA [9].
At least two phenotypes can be distinguished in GPA; limited
disease (less severe), and diffuse disease (more severe) [1]. The
current expert consensus deﬁnes limited disease as manifestations
that are neither organ nor life threatening, in contrast to diffuse
disease which is organ or life threatening [1]. Approximately one
quarter of cases present as limited disease, and limited disease is
more common in young females [1]. Otolaryngeal involvement is
also more prevalent in subset of patients with limited disease,
while renal involvement occurs much less commonly. Rates of
pulmonary involvement are equivalent between limited and
diffuse disease, however limited disease does not present with
alveolar hemorrhage [1]. Further, the sensitivity of ANCA testing
lacks in limited disease compared to diffuse disease (67% vs 91%)
[1].
Earlier reports hypothesized that limited and diffuse GPA were
entities along the same disease spectrum; suggesting that limited
disease would eventually evolve to severe disease if allowed to
develop in the absence of treatment [10]. However, pathological
patterns have emerged illustrating that the presence of vasculitis
may characterize more diffuse disease, while granulomatous
inﬂammation is more prevalent in the limited subset [1]. At the
cellular immune level, a Th1 mediated process predominates in
granulomatous inﬂammation in contrast to a Th2 pattern in the
vasculitic subset [11]. This could suggest that limited and diffuse
disease are distinct entities, and limited disease may not always
progress to severe life-threatening disease.The distinction between diffuse and limited disease is very
important because of the implications for therapy [1]. Severe GPA
requires prompt use of aggressive induction agents, including high
dose glucocorticioids and cyclophosphamide, while limited disease
responds well to less toxic agents such as methotrexate plus
prednisone [12]. In either limited or diffuse disease, clinical
remission is usually achieved within three to six months after in-
duction treatment, and patients can be transitioned tomaintenance
therapy regimens [12]. Maintenance therapy regimens are less
immunosuppressive than induction therapy, and generally use
tapering doses of glucocorticoids and a less potent immunosup-
pressive agent such as azathioprine (or continuation of metho-
trexate in the context of limited disease).
Close follow up during induction and maintenance therapy is
important to monitor for drug toxicities, infections, and disease
relapses [12]. The rate of disease relapse occurs in 18%e40% within
24 months, and occurs more often in patients with limited disease
[1,12].
In summary, this case highlights the importance of considering
GPA as a differential diagnosis in the course of non-resolving
airspace disease seen on chest imaging. Core needle biopsy (for
pathology and culture analysis) is a legitimatemeans to conﬁrm the
diagnosis when there is lung involvement, and can be performed in
aminimally-invasive fashion. Isolated lung involvement is rare, and
it is important to search for other systemic manifestations of GPA at
the time of diagnosis, and during follow up. Recognizing the dif-
ference between limited and diffuse disease is important, as this
affects the type of treatment, prognosis, and relapse rate.Patient consent
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